Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 10Melanoma 8Lung Neoplasms 8Neoplasms 7Carcinoma 6Skin Neoplasms 5Neoplasm Metastasis 5Carcinoma, Squamous Cell 5Carcinoma, Basal Cell 5Adenocarcinoma 5Sarcoma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Recurrence 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Hemangiosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

Gemcitabine 13Doxorubicin 8Docetaxel 7Trabectedin 5pazopanib 4Nivolumab 4Temozolomide 3Specimen Handling 3Sorafenib 3rucaparib 2pembrolizumab 2liposomal doxorubicin 2durvalumab 2brostallicin 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Magnetic Resonance Spectroscopy 2Letrozole 2Ifosfamide 2Dacarbazine 2Bevacizumab 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1talimogene laherparepvec 1sotigalimab 1soblidotin 1saracatinib 1rubitecan 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leiomyosarcoma × cemiplimab × Clear all
NCT06528769 2025-09-30

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
16 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡